Acceleron Pharma
XLRN
XLRN was delisted on the 19th of November, 2021.
162 hedge funds and large institutions have $1.94B invested in Acceleron Pharma in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 53 increasing their positions, 54 reducing their positions, and 31 closing their positions.
642% more call options, than puts
Call options by funds: $27.2M | Put options by funds: $3.66M
0.83% less ownership
Funds ownership: 97.3% → 96.46% (-0.83%)
2% less repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 54
3% less funds holding
Funds holding: 167 → 162 (-5)
16% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 31
24% less capital invested
Capital invested by funds: $2.56B → $1.94B (-$619M)
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$36.6M |
| 2 |
DM
Deerfield Management
New York
|
+$13.4M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$13M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$12.8M |
| 5 |
Bank of New York Mellon
New York
|
+$12.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$46.6M |
| 2 |
PA
Perceptive Advisors
New York
|
-$31.1M |
| 3 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$11.5M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$10.5M |
| 5 |
Brown Advisory
Baltimore,
Maryland
|
-$10.3M |
XLRN Hedge Fund Activity: Q4 2018 in Review
162 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2018, worth a combined $1.94B — down 24% from $2.56B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of XLRN and 26 opened new positions — a net loss of 5 holders — while 54 trimmed existing stakes and 53 added.
The largest buyer was Point72 Asset Management, adding an estimated $36.6M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $46.6M sold.
- 162 institutional investors held Acceleron Pharma (XLRN) as of Q4 2018, down from 167 in Q3 2018.
- Funds reported $1.94B of Acceleron Pharma stock for Q4 2018, down 24% quarter-over-quarter.
- 26 funds opened new Acceleron Pharma positions in Q4 2018 and 31 closed out, a net change of -5 holders.
- The largest Acceleron Pharma buyer in Q4 2018 was Point72 Asset Management, an estimated $36.6M added.
- The largest Acceleron Pharma seller in Q4 2018 was Hillhouse Investment Management, an estimated $46.6M sold.
Based on aggregated 13F filings for Q4 2018.